newsfilter
← Latest News
GlobeNewswire·

CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026

VANCOUVER, Washington, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized